3.4.24.84	1,10-phenanthroline	Zn2+ chelator	62	
3.4.24.84	atazanavir	-	2379	
3.4.24.84	benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone	0.25 mM, 21% inhibition, inhibition is not reversible	14206	
3.4.24.84	benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone	0.25 mM, 41% inhibition, inhibition is not reversible	14206	
3.4.24.84	benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone	0.25 mM, 22% inhibition, inhibition is not reversible	14206	
3.4.24.84	benzyloxycarbonyl-Phe-Lys-2,4,6-trimethylbenzoyloxymethyl ketone	0.25 mM, 76% inhibition, inhibition is not reversible	14205	
3.4.24.84	benzyloxycarbonyl-Phe-Lys-2,4,6-trimethylbenzoyloxymethyl ketone	0.25 mM, 68% inhibition, inhibition is not reversible	14205	
3.4.24.84	darunavir	-	1901	
3.4.24.84	lopinavir	HIV protease inhibitors inhibit ZMPSTE24, leading to an accumulation of farnesyl-prelamin A. The inhibition of ZMPSTE24 by HIV protease inhibitors could play a role in the side effects of these drugs	1430	
3.4.24.84	lopinavir	-	1430